methyl 2-[3-(3-cyanophenyl)-5-[[4-(2-methoxyphenyl)phenyl]carbamoyl]-4H-1,2-oxazol-5-yl]acetate | 1025943-55-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-[3-(3-cyanophenyl)-5-[[4-(2-methoxyphenyl)phenyl]carbamoyl]-4H-1,2-oxazol-5-yl]acetate
• CAS: 1025943-55-8
• 化学式: C₂₇H₂₃N₃O₅
• 分子量: 469.497
• InChiKey: HABUECPJFNFHAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  methyl 2-[3-(3-cyanophenyl)-5-[[4-(2-methoxyphenyl)phenyl]carbamoyl]-4H-1,2-oxazol-5-yl]acetate 在 盐酸 、 ammonium acetate 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 24.0h， 生成 5-isoxazoleacetic acid, 3-<3-(aminoiminomethyl)phenyl>-5-<<<2'-methoxy<1,1'-biphenyl>-4-yl>amino>carbonyl>-4,5-dihydro-, methyl ester
  参考文献：
  名称：

  Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. 1

  摘要：

  Thrombosis is a major cause of mortality in the industrialized world. Therefore, the prevention of blood coagulation has become a major target for new therapeutic agents. One attractive approach is the inhibition of factor Xa (FXa), the enzyme directly responsible for protbrombin activation. We report a series of novel biaryl-substituted isoxazoline derivatives in which the biaryl moiety was designed to interact with the S-4 aryl-binding domain of the FXa active site. Several of the compounds herein have low nanomolar affinity for FXa, have good in vitro selectivity for FXa, and show potent antithrombotic efficacy in vivo, The three most potent compounds (33, 35, and 37) have inhibition constants for human FXa of 3.9, 2.3, and 0.83 nM, respectively, and ID50's ranging from 0.15 to 0.26 mu mol/kg/h in the rabbit arterio-venous thrombosis model.

  DOI：

  10.1021/jm980405i
• 作为产物：
  描述：

  3-cyanobenzaldehyde oxime 在 sodium hypochlorite 、 氯化亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 13.0h， 生成 methyl 2-[3-(3-cyanophenyl)-5-[[4-(2-methoxyphenyl)phenyl]carbamoyl]-4H-1,2-oxazol-5-yl]acetate
  参考文献：
  名称：

  Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. 1

  摘要：

  Thrombosis is a major cause of mortality in the industrialized world. Therefore, the prevention of blood coagulation has become a major target for new therapeutic agents. One attractive approach is the inhibition of factor Xa (FXa), the enzyme directly responsible for protbrombin activation. We report a series of novel biaryl-substituted isoxazoline derivatives in which the biaryl moiety was designed to interact with the S-4 aryl-binding domain of the FXa active site. Several of the compounds herein have low nanomolar affinity for FXa, have good in vitro selectivity for FXa, and show potent antithrombotic efficacy in vivo, The three most potent compounds (33, 35, and 37) have inhibition constants for human FXa of 3.9, 2.3, and 0.83 nM, respectively, and ID50's ranging from 0.15 to 0.26 mu mol/kg/h in the rabbit arterio-venous thrombosis model.

  DOI：

  10.1021/jm980405i

文献信息

• Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. 1
  作者：Mimi L. Quan、Ann Y. Liauw、Christopher D. Ellis、James R. Pruitt、David J. Carini、Lori L. Bostrom、Peggy P. Huang、Kimberly Harrison、Robert M. Knabb、Martin J. Thoolen、Pancras C. Wong、Ruth R. Wexler

  DOI：10.1021/jm980405i

  日期：1999.7.1

  Thrombosis is a major cause of mortality in the industrialized world. Therefore, the prevention of blood coagulation has become a major target for new therapeutic agents. One attractive approach is the inhibition of factor Xa (FXa), the enzyme directly responsible for protbrombin activation. We report a series of novel biaryl-substituted isoxazoline derivatives in which the biaryl moiety was designed to interact with the S-4 aryl-binding domain of the FXa active site. Several of the compounds herein have low nanomolar affinity for FXa, have good in vitro selectivity for FXa, and show potent antithrombotic efficacy in vivo, The three most potent compounds (33, 35, and 37) have inhibition constants for human FXa of 3.9, 2.3, and 0.83 nM, respectively, and ID50's ranging from 0.15 to 0.26 mu mol/kg/h in the rabbit arterio-venous thrombosis model.